BioPharmSignal logoBioPharmSignal

Biotech News

Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland

Outlook (OTLK)OutlookCommercial

Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partner Mediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab gamma) in Switzerland Partnership advances European commercial expansion strategy,

Open original release

Related news

OTLKOutlook2026-06-01 12:46 EST

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

OTLKOutlook2026-05-26 11:00 EST

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

LENZLenz Therapeutics Inc2026-07-06 12:15 EST

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

LENZLenz Therapeutics Inc2026-01-14 13:30 EST

LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign

VRDNViridian Therapeutics2022-01-04 12:00 EST

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

VRDNViridian Therapeutics2021-12-20 12:00 EST

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

LCTXLineage Cell Therapeutics2026-05-05 12:00 EST

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

LCTXLineage Cell Therapeutics2026-02-26 13:00 EST

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

View all latest news

Outlook

Outlook Therapeutics is an ophthalmology company focused on retinal disease and anti-VEGF therapy delivery. Its story centers on whether it can create a differentiated eye-care franchise.

Recent company news

OTLKOutlook2026-06-01 12:46 EST

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

OTLKOutlook2026-05-28 20:00 EST

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

OTLKOutlook2026-05-26 11:00 EST

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

OTLKOutlook2026-05-15 20:05 EST

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

OTLKOutlook2026-04-23 20:05 EST

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

Stock data

Close
1.07 USD
Market cap
120.89M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States